Bridgewater Associates’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.81M | Buy |
39,237
+6,313
| +19% | +$1.57M | 0.04% | 290 |
|
|
2025
Q4 | $7.93M | Buy |
32,924
+942
| +3% | +$241K | 0.03% | 412 |
|
|
2025
Q3 | $8.75M | Buy |
31,982
+26,728
| +509% | +$7.3M | 0.03% | 356 |
|
|
2025
Q2 | $1.36M | Sell |
5,254
-114,077
| -96% | -$27.2M | 0.01% | 450 |
|
|
2025
Q1 | $26.7M | Buy |
119,331
+32,060
| +37% | +$7.48M | 0.12% | 146 |
|
|
2024
Q4 | $20M | Sell |
87,271
-6,626
| -7% | -$1.6M | 0.09% | 167 |
|
|
2024
Q3 | $22.9M | Sell |
93,897
-72,216
| -43% | -$16.1M | 0.13% | 139 |
|
|
2024
Q2 | $31.8M | Buy |
166,113
+17,407
| +12% | +$3.53M | 0.17% | 99 |
|
|
2024
Q1 | $29.4M | Sell |
148,706
-9,820
| -6% | -$1.8M | 0.15% | 111 |
|
|
2023
Q4 | $27.3M | Sell |
158,526
-71,997
| -31% | -$11.1M | 0.15% | 107 |
|
|
2023
Q3 | $34.1M | Buy |
230,523
+58,199
| +34% | +$10.5M | 0.21% | 89 |
|
|
2023
Q2 | $37.7M | Sell |
172,324
-20,537
| -11% | -$4.58M | 0.23% | 82 |
|
|
2023
Q1 | $42.2M | Sell |
192,861
-20,312
| -10% | -$4.41M | 0.26% | 78 |
|
|
2022
Q4 | $44.4M | Sell |
213,173
-53,593
| -20% | -$11.8M | 0.24% | 85 |
|
|
2022
Q3 | $58.2M | Buy |
266,766
+23,845
| +10% | +$5.43M | 0.29% | 71 |
|
|
2022
Q2 | $50.9M | Sell |
242,921
-27,869
| -10% | -$5.93M | 0.22% | 98 |
|
|
2022
Q1 | $65.7M | Buy |
270,790
+83,388
| +44% | +$20.2M | 0.26% | 70 |
|
|
2021
Q4 | $48.8M | Buy |
187,402
+26,053
| +16% | +$6.76M | 0.28% | 67 |
|
|
2021
Q3 | $42.5M | Sell |
161,349
-3,466
| -2% | -$948K | 0.23% | 82 |
|
|
2021
Q2 | $40.6M | Buy |
164,815
+75,028
| +84% | +$15.8M | 0.26% | 79 |
|
|
2021
Q1 | $17.4M | Buy |
89,787
+15,508
| +21% | +$3.11M | 0.15% | 114 |
|
|
2020
Q4 | $15.8M | Buy |
74,279
+37,854
| +104% | +$7.55M | 0.14% | 95 |
|
|
2020
Q3 | $6.24M | Buy |
+36,425
| New | +$6.73M | 0.08% | 120 |
|
|
2020
Q2 | – | Sell |
-3,371
| Closed | -$497K | – | 489 |
|
|
2020
Q1 | $497K | Buy |
+3,371
| New | +$537K | 0.01% | 288 |
|
|
2019
Q1 | – | Sell |
-8,119
| Closed | -$925K | – | 468 |
|
|
2018
Q4 | $925K | Buy |
+8,119
| New | +$870K | 0.01% | 339 |
|
|
2018
Q3 | – | Sell |
-5,565
| Closed | -$576K | – | 456 |
|
|
2018
Q2 | $576K | Sell |
5,565
-4,067
| -42% | -$412K | 0.01% | 307 |
|
|
2018
Q1 | $948K | Buy |
+9,632
| New | +$910K | 0.01% | 271 |
|
|
2016
Q2 | – | Sell |
-49,576
| Closed | -$2.87M | – | 372 |
|
|
2016
Q1 | $2.87M | Buy |
+49,576
| New | +$2.81M | 0.04% | 169 |
|
|
2015
Q4 | – | Sell |
-13,788
| Closed | -$703K | – | 383 |
|
|
2015
Q3 | $703K | Buy |
13,788
+7,800
| +130% | +$420K | 0.01% | 273 |
|
|
2015
Q2 | $338K | Buy |
+5,988
| New | +$378K | ﹤0.01% | 290 |
|
Other funds holding RMD
VCM
VPM
DAM
Bridgewater Associates's RMD Position: Q1 2026 in Review
Bridgewater Associates increased its ResMed (RMD) stake by 19% in Q1 2026, buying an estimated $1.57M and bringing the position to 39,237 shares worth $8.81M. The position accounts for 0.04% of the portfolio, ranked #290.
Bridgewater Associates first reported a position in RMD in Q2 2015 and has held it in 30 quarters since. The position peaked at $65.7M in Q1 2022. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.
- Bridgewater Associates held 39,237 shares of ResMed worth $8.81M as of Q1 2026.
- Bridgewater Associates bought 6,313 ResMed shares in Q1 2026, an estimated $1.57M.
- ResMed made up 0.04% of Bridgewater Associates's portfolio in Q1 2026, its #290 holding.
- Bridgewater Associates first reported a position in ResMed in Q2 2015 and has held it in 30 quarters since.
- Bridgewater Associates's ResMed position peaked at $65.7M in Q1 2022.
- 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.
Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.